Partnership Awards
Partnership Awards support researchers collaborating across academia, industry, and nonprofit organizations on translational research to advance melanoma prevention, diagnosis, staging, and treatment.
Browse similar grants
Funder: Melanoma Research Alliance
Due Dates: August 21, 2026 (Academic-Industry Partnership LOI) | December 10, 2026 (Invited full proposals)
Funding Amounts: At least $7.9 million planned across MRA’s 2026–2027 funding cycle
Summary: Partnership Awards support cross-sector collaboration to advance innovative, translational research in melanoma prevention, diagnosis, staging, and treatment.
Key Information: The 2026–2027 cycle includes an Academic-Industry Partnership Award within the Established Investigator Awards, with full proposals by invitation.
Description
The Melanoma Research Alliance (MRA) Partnership Awards are designed to facilitate interactions between sectors, including industry and other nonprofit organizations. They form part of MRA’s broader portfolio supporting innovative, translational research with the potential to influence melanoma prevention, diagnosis, staging, and treatment in the near and intermediate future. That portfolio includes both individual-investigator and collaborative team projects.
For the 2026–2027 cycle, MRA includes an Academic-Industry Partnership Award within its Established Investigator Awards. The cycle seeks pre-clinical, translational, and early clinical research with the potential to produce unusually high-impact, near-term advances in melanoma prevention, detection, diagnosis, and treatment. The partnership mechanism’s distinctive emphasis is on cross-sector interaction within this melanoma research focus.
